Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.

Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial. JAMA Surg. 2022 11 01; 157(11):1034-1041.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Carcinoma, Ductal, Breast
Carcinoma, Intraductal, Noninfiltrating
Female
Humans
Middle Aged
Neoadjuvant Therapy
Neoplasm Recurrence, Local
Neoplasm, Residual
Receptor, ErbB-2
Retrospective Studies
Young Adult

authors with profiles

Nora T. Jaskowiak
Husain Sattar